A Phase III Study (a Placebo Controlled, Randomized, Double-blind Comparative Study and an Open-label, Uncontrolled Study) to Evaluate the Efficacy and Safety of GSK1358820 in Patients With Post-stroke Upper Limb Spasticity
Phase of Trial: Phase III
Latest Information Update: 19 Oct 2019
Price : $35 *
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscle spasticity
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Jan 2019 Status changed from active, no longer recruiting to completed.
- 09 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2017 New trial record